Dissociation of cocaine-antagonist properties and motoric effects of the D1 receptor partial agonists SKF 83959 and SKF 77434

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 3, 2000, Pages 1017-1026

  Platt, Donna M ^a   Rowlett, James K ^a   Spealman, Roger D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; BENZAZEPINE DERIVATIVE; COCAINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ECOPIPAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; SQUIRREL MONKEY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BENZAZEPINES; CATALEPSY; COCAINE; DISCRIMINATION LEARNING; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCLE RIGIDITY; RECEPTORS, DOPAMINE D1; SAIMIRI;

EID: 0034124221     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Andersen PH and Jansen JA (1990) Dopamine receptor agonists: Selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol 188:335-347.
2. Andringa G, Drukarch B, Leysen JE, Cools AR and Stoof JC (1999a) The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Eur J Pharmacol 364:33-41.
3. Andringa G, Stoof JC and Cools AR (1999b) Sub-chronic administration of the D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: Stable therapeutic effects and wearing-off dyskinesia. Psychopharmacohgy 146:328-334.
4. Ariens EJ (1983) Intrinsic activity: Partial agonists and partial antagonists. J Cardiovasc Pharmacol 5:S8-S15.
5. Arnt J, Hyttel J and Sánchez C (1992) Partial and full dopamine D1 receptor agonists in mice and rats: Relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213:259-267.
6. Bergman J and Rosenzweig-Lipson S (1992) Cocaine-antagonist effects of limited-efficacy D1 agonists. NIDA Res Monogr 119:185-189.
7. Caine SB, Negus SS, Mello NK and Bergman J (1999) Effects of dopamine D1-like and D2-like agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 291:353-360.
8. Callahan PM and Cunningham KA (1993) Discriminative stimulus effects of cocaine in relation to dopamine D2 receptor function in rats. J Pharmacol Exp Ther 266:585-592.
9. 1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93:1483-1489.
10. Colpaert FC (1994) Noradrenergic mechanisms in Parkinson's disease: A theory, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M and Marien M eds) pp 225-254, CRC Press, Ann Arbor, MI.
11. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P and Marsden CD (1995) Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117:275-286.
12. Holtzman SG (1990) Discriminative stimulus effects of drugs: Relationship to potential for abuse, in Testing and Evaluation of Drugs of Abuse, Modern Methods in Pharmacology, vol 6, pp 193-210, Wiley-Liss, New York.
13. Hurd YL, Kehr J and Ungerstedt U (1988) In vivo microdialysis as a technique to monitor drug transport: Correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J Neurochem 51:1314-1316.
14. Kalkman HO, Neumann V, Hoyer D and Tricklebank MD (1998) The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556.
15. Katz JL and Witkin JM (1992) Selective effects of the D1 dopamine receptor agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkeys. Psychopharmacology 109:241-244.
16. Katz JL, Kopajtic TA, Myers KA, Mitkus RJ and Chider M (1999) Behavioral effects of cocaine: Interactions with D1 dopaminergic antagonists and agonists in mice and squirrel monkeys. J Pharmacol Exp Ther 291:265-279.
17. Koller WC and Rueda MG (1998) Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 50:S11-S48.
18. Kosten TR and McCance E (1996) A review of pharmacotherapies for substance abuse. Am J Addict 5:58-65.
19. Meltzer HY (1993) New drugs for the treatment of schizophrenia. Schizophrenia 16:365-385.
20. Mendelson JH and Mello NK (1996) Management of cocaine abuse and dependence. N Engl J Med 334:965-972.
21. Meyer ME and Shults JM (1993) Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats. Pharmacol Biochem Behav 46:269-274.
22. Morelli M and Di Chiara G (1985) Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol 117:179-185.
23. Murray AM and Waddington JL (1989) The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: Two directions of D-1:D-2 interaction. Eur J Pharmacol 160:377-384.
24. Novak MA, O'Neill P and Suomi SJ (1992) Adjustments and adaptations to indoor and outdoor environments: Continuity and change in young adult rhesus monkeys. Am J Primatol 28:124-138.
25. Petit HO and Justice JB (1989) Dopamine in the nucleus accumbens during cocaine self-administration as studies by in vivo microdialysis. Pharmacol Biochem Behav 34:899-904.
26. Pfeiffer FR, Wilson JW, Weinstock J, Kuo GY, Chambers PA, Holden KG, Hahn RA, Wardell JR, Tobia AJ, Setler PE and Sarau HM (1982) Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines. J Med Chem 25:352-358.
27. Platt DM, Spealman RD and Rowlett JK (1998) Cocaine-antagonist properties of the D1 partial agonist SKF 83959 in squirrel monkeys. NIDA Res Monogr 179:178.
28. Pulvirenti L, Balducci C, Piercy M and Koob GF (1998) Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 286:1231-1238.
29. Pulvirenti L and Koob GF (1994) Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 15:374-379.
30. Rosenzweig-Lipson S and Bergman J (1994) Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys. Eur J Pharmacol 260:237-241.
31. Self DW and Stein L (1992) The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Res 582:349-352.
32. Spealman RD (1995) Discriminative stimulus effects of cocaine in squirrel monkeys: Lack of antagonism by the dopamine D2 partial agonists terguride, SDZ 208-911, and SDZ 208-912. Pharmacol Biochem Behav 51:661-665.
33. Spealman RD, Barrett-Larimore RL, Rowlett JK, Platt DM and Khroyan TV (1999) Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol Biochem Behav 64:327-336.
34. Spealman RD, Bergman J, Madras BK and Melia KF (1991) Discriminative stimulus effects of cocaine in squirrel monkeys: Involvement of dopamine receptor subtypes. J Pharmacol Exp Ther 258:945-953.
35. Spealman RD, Bergman J and Rosenzweig-Lipson S (1997) Differential modulation of behavioral effects of cocaine by low-and high-efficacy D1 agonists. Psychopharmacology 133:283-292.
36. Spealman RD, Madras BK and Bergman J (1989) Effects of cocaine and related drugs in nonhuman primates: II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142-149.
37. Undie AS, Weinstock J, Sarau HM and Friedman E (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem 62:2045-2048.
38. Warner EA, Kosten TR and O'Connor PG (1997) Pharmacotherapy for opioid and cocaine abuse. Med Clin N Am 81:909.
39. Weed MR, Paul IA, Dwoskin LP, Moore SE and Woolverton WL (1997) The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys. J Pharmaccl Exp Ther 283:29-38.
40. Weed MR, Woolverton WL and Paul IA (1998) Dopamine D1 and D2 receptor selectivities of phenyl-benzazepines in rhesus monkey striata. Eur J Pharmacol 361:129-142.
41. Weissenborn R, Deroche V, Koob GF and Weiss F (1996) Effects of dopamine agonists and antagonists on cocaine-induced operant responding for a cocaine-associated stimulus. Psychopharmacology 126:311-322.